|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07H 21/02 | (2006.01) |
| C07H 21/02 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 35/00 | (2018.01) |
| (11) | Number of the document | 3762397 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19712440.7 |
| Date of filing the European patent application | 2019-03-07 | |
| (97) | Date of publication of the European application | 2021-01-13 |
| (45) | Date of publication and mention of the grant of the patent | 2024-05-01 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2019/021145 |
| Date | 2019-03-07 |
| (87) | Number | WO 2019/173587 |
| Date | 2019-09-12 |
| (30) | Number | Date | Country code |
| 201862640325 P | 2018-03-08 | US |
| (72) |
FINK, Brian E. , US
RUAN, Zheming , US
|
| (73) |
Bristol-Myers Squibb Company ,
Route 206 and Province Line Road, Princeton, NJ 08543,
US
|
| (54) | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS |
| CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS |